Inclusion Criteria:

- Must be 18 years of age or older with histologic diagnosis of soft tissue sarcoma

- Must have disease not suitable for curative resection

- Must have failed >1 first line treatment with evidence of progression. Adjuvant
therapy does not count as 1st line therapy unless recurrence occurs within 6 months
of administration

- Must have ability to understand and the willingness to sign a written informed
consent document

- Must have Eastern Cooperative Oncology Group (ECOG) performance status of < 2

- Must have measurable disease according to Response Evaluation Criteria in Solid
Tumors (RECIST) criteria

- At least 4 weeks have passed since the last chemotherapy, immunotherapy, or
radiation therapy

- There must be measurable disease outside the radiotherapy fields or progression of
the indicator lesions within the field since the completion of the radiotherapy

- Must have a life expectancy of greater than 12 weeks

- Must have clinical laboratory values at screening as defined below:

- Hemoglobin >9 g/dL,

- Absolute neutrophil count >1500/mm3,

- Platelet count >100,000/mm3,

- Creatinine <1.5 X ULN,

- Bilirubin <1.5 X ULN,

- Asparate aminotransferase and alanine aminotransferase <2.5 X ULN (<5 X ULN in
presence of liver metastases)

Exclusion Criteria:

- Female patients who are pregnant or breast feeding

- Patients of childbearing potential not using or not willing to use a barrier method
of contraception

- Prior malignancy other than soft tissue sarcoma (STS) within the last 5 yrs with the
exception of:

- Adequately treated in situ carcinoma of the cervix uteri;

- Basal or squamous cell carcinoma of the skin

- Presence of a clinically significant and uncontrolled infection

- Presence of >Grade 2 neuropathy

- Symptomatic central nervous system metastases within last 8 weeks or on
corticosteroids for CNS symptom management

- Presence of clinically significant arrythmias

- Presence of a serious concurrent illness or other conditions (e.g., psychological,
family, sociological, or geographical circumstances) that do not permit adequate
follow-up and compliance with the protocol

- History of severe hypersensitivity reactions to taxanes or cremaphore in spite of
premedication

- Use of any investigational agents within 4 weeks prior to the first dose of study
drug(s)

- Major surgery within 2 weeks of screening

- Radiation treatment in past >25% of bone marrow